Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HXN-1013 SAD Study in Healthy Participants and Mild-to-Moderate Asthma
NCT07900568Phase 1Not yet recruiting
- Sponsor
- Helixon
- Start
- Dec 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HY-6725 in asthma (4 arms), sponsored by Helixon. Primary endpoint: Adverse Events at Day 141. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
HY-6725
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07900568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900568.